Related Experiment Video

Updated: Dec 21, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

952

Inhibitor of Differentiation 1 (Id1) in Cancer and Cancer Therapy

Zhengxiao Zhao1, Zhiyuan Bo2, Weiyi Gong3

  • 1Department of Oncology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China.

International Journal of Medical Sciences
|May 16, 2020
PubMed

Insights

Inhibitor of DNA binding 1 (Id1) promotes cancer growth, metastasis, and drug resistance by regulating key signaling pathways. Targeting Id1 offers a promising therapeutic strategy for various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Inhibitor of DNA binding (Id) proteins regulate cell cycle and differentiation.
  • Id1 is implicated in tumorigenesis, senescence, proliferation, and survival, acting as a stem cell-like gene.
  • Id1 overexpression is observed in many cancers, promoting tumor progression.

Purpose of the Study:

  • To review the multifaceted roles of Id1 in cancer development and progression.
  • To explore Id1's involvement in various signaling pathways crucial for tumorigenesis.
  • To assess Id1's impact on angiogenesis, metastasis, and drug resistance.

Main Methods:

  • Literature review of studies investigating Id1 function in cancer.
  • Analysis of Id1's correlation with key signaling pathways (e.g., EMT, Ras, EGFR, BMP, PI3K/Akt, WNT, SHH, Myc, STAT3, MAPK, TGF-β).
  • Examination of Id1's role in angiogenesis, metastasis, and drug resistance.

Main Results:

  • Id1 overexpression is linked to numerous cancer types and promotes tumor growth.
  • Id1 significantly correlates with multiple oncogenic signaling pathways.
  • Id1 facilitates tumor angiogenesis, metastasis, and the development of resistance to various cancer therapies.
  • Controversial findings regarding Id1's role were also noted.

Conclusions:

  • Id1 is a crucial promoter of cancer progression, angiogenesis, metastasis, and drug resistance.
  • Id1 represents a promising therapeutic target for anti-cancer drug development.
  • Several drugs demonstrate anti-tumor effects through Id1-related pathways.
Keywords:
AngiogenesisCancerId1ResistanceSignaling pathwayTarget

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K